UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 18, 2019
Mustang Bio, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
001-38191 |
|
47-3828760 |
2 Gansevoort Street, 9th Floor
New York, NY 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act. |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
¨ | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.0001 per share | MBIO | NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.07. | Submission of Matters to a Vote of Security Holders. |
Mustang Bio, Inc. (“Mustang”) held its annual meeting of stockholders on June 18, 2019 at the offices of its legal counsel, Alston & Bird LLP, 90 Park Avenue, New York, New York 10016 at 3:00 p.m. Eastern Time. Stockholders representing 29,120,794, or 89.69% of the 32,466,310 shares entitled to vote were represented in person or by proxy constituting a quorum. At the annual meeting, the following three proposals were approved: the election of six directors to hold office until the 2020 annual meeting, the ratification of the appointment of BDO USA, LLP as Mustang’s independent registered public accounting firm for the year ending December 31, 2019, and the approval Mustang’s 2019 Employee Stock Purchase Plan. The three proposals are described in detail in Mustang’s definitive proxy statement dated April 30, 2019 for the annual meeting.
Proposal 1
The votes with respect to the election of six directors to hold office until the 2020 annual meeting were as follows:
Director | For | % Voted For | Withheld | % Voted Withheld |
Michael S. Weiss | 13,866,358 | 86.41% | 2,180,459 | 13.59% |
Lindsay A. Rosenwald, M.D. | 13,865,850 | 86.41% | 2,180,967 | 13.59% |
Neil Herskowitz | 13,552,502 | 84.46% | 2,494,315 | 15.54% |
Manuel Litchman, M.D. | 14,210,377 | 88.56% | 1,836,440 | 11.44% |
Adam Chill | 14,605,844 | 91.02% | 1,440,973 | 8.98% |
Michael Zelefsky, M.D. | 14,605,259 | 91.02% | 1,441,558 | 8.98% |
Proposal 2
The votes with respect to the ratification of BDO USA, LLP as Mustang’s independent registered accounting firm for the year ending December 31, 2019 was as follows:
Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
28,860,622 | 169,671 | 90,501 | 0 |
Proposal 3
The votes with respect to the approval of Mustang’s 2019 Employee Stock Purchase Plan was as follows:
Total Votes For | Total Votes Against | Abstentions | Broker Non-Votes |
15,911,162 | 119,177 | 16,478 | 13,073,977 |
In addition, holders of all of Mustang’s issued and outstanding Class A Preferred Stock voted all of their preferred shares in favor of each of the three proposals above.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 19, 2019 | Mustang Bio, Inc. | ||
(Registrant) | |||
By: | /s/ Manuel Litchman, M.D. | ||
Manuel Litchman, M.D. | |||
President and Chief Executive Officer |